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Abstract
Keloid disease is characterized by hyperproliferation of re-
sponsive fibroblasts with vigorously continuous synthesis of
extracellular matrix (ECM) components. Although the pro-
cess by which keloids develop is poorly understood, most
theories of the etiology are referred to fibroblast dysfunction.
A central event in dermal repair is the release of growth factors
in response to skin injury, which leads to the dysregulation of
several crucial pathways that initiate the activation of keloid
fibroblasts (KFs) and promote ECM accumulation. Hence,
strategies aimed at reducing the production of these cytokines
and/or disrupting their intracellular signal transduction have
potential clinical significance for curing keloid. As the first
oral multikinase inhibitor, sorafenib blocks a number of intra-
cellular signaling pathways which are also pivotal for keloid
pathogenesis. Therefore, evaluation of the effects of sorafenib
on keloid disease seems timely and pertinent. In this study, we
reported the identification of sorafenib that antagonized
TGF-β/Smad and MAPK/ERK signaling pathways in prima-
ry KFs. Impressively, treatment with sorafenib inhibited KF
cell proliferation, migration, and invasion, and simultaneously
reduced collagen production in KFs. Furthermore, we present
ex vivo evidence that sorafenib induced the arrest of KF mi-
gration, the inhibition of angiogenesis, and the reduction of
collagen accumulation. These preclinical observations suggest
that sorafenib deserves systematic exploration as a candidate
agent for the future treatment of keloids.
Key message
& The intracellular TGF-β/Smad and MAPK/ERK signal-
ing pathways is blocked by sorafenib.
& Sorafenib inhibits the proliferation, migration, invasion,
and ECM deposition in keloid fibroblasts.
& Sorafenib reduces KFmigration and concomitantly angio-
genesis in keloid explants.
& Sorafenib is a promising agent for the treatment of keloids
and hypertrophic scars.
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Introduction
As an abnormal process of wound healing, keloids appear as
firm, rubbery lesions or glossy, fibrous nodules. Unique to
humans, keloids are characterized by an uncontrolled growth
of dermal fibroblasts with an excessive production of the extra-
cellular matrix (ECM), especially collagen types I (late), III
(early), fibronectin, and other ECM proteins such as elastin
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and periostin [1, 2]. The prevalence of keloids and the risk of
recurrence are relatively high in people of Asian or African
descent with a genetic predisposition [3, 4], which have
plagued physicians and patients for centuries. Although multi-
ple localized therapeutic modalities exist, including surgical
excision, cryotherapy, topical drug injection, and radiotherapy
[5, 6], the clinical results remain unsatisfactory.
Simultaneously, the adverse effects and inconvenience of the
current treatments result in poor patient compliance, signifying
that the treatment of keloids is a thorny issue. Hence, research
efforts on the pathogenetic mechanisms underlying keloid for-
mation and development are imperative for curing this disease.
The molecular basis of keloids is complicated and involves
both genetic and environmental factors, such as gene muta-
tions, aberrant cytokine expression, inflammatory responses,
and UV exposure [3, 7]. Although the etiology of keloids
remains largely unknown, the histopathological hallmarks of
this disease are referred to fibroblast dysfunction. Primary
fibroblasts isolated from human keloids exhibit a typical spin-
dle morphology that is similar to the size and shape of normal
dermal fibroblasts, but they possess tumor-like properties with
a great capacity for cell proliferation, migration, and high pro-
duction of collagens and certain growth factors [1, 8]. Among
these mediators, transforming growth factor-β (TGF-β) is be-
lieved to be a master inducer of keloid development [9]. Of
note, the expression levels of biologically active isoforms of
TGF-β ligands and their receptors are markedly elevated in
keloid fibroblasts (KFs) compared with normal dermal fibro-
blasts [10, 11]. Furthermore, TGF-β is vital for cell prolifera-
tion and collagen synthesis in KFs, whereas KFs display a
distinct sensitivity to TGF-β stimulation [12, 13]. In addition
to TGF-β signaling, a multitude of cytokines have been re-
ported to be dysregulated in keloid pathogenesis and recur-
rence, such as vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) [1, 9]. These secreted
molecules regulate a broad array of intracellular responses in
keloids including ECM production and deposition, fibroblast
proliferation, angiogenesis, and inflammatory cell infiltration.
Therefore, attempts to reduce the synthesis of selected cyto-
kines or block their associated signal transduction may pro-
vide an alternative potential approach for keloid treatment.
Over the past decades, the discovery and development of
small molecules that target multiple signaling pathways have
revolutionized the fight against cancer. Most notably, sorafe-
nib (trade name: Nexavar) is the first oral multikinase inhibitor
that was approved by the Food and Drug Administration
(FDA) for the treatment of patients with a broad range of
tumor types [14, 15]. As a potent tyrosine kinase inhibitor
(TKI), sorafenib blocks tumor angiogenesis and progression
by targeting Raf kinase and several receptor tyrosine kinases,
including VEGF receptor 2 (VEGFR2) and PDGF receptor β
(PDGFRβ) [16]. Histologically, keloids are benign fibrotic
tumors of the dermis characterized by a collection of atypical
fibroblasts with overexpression of cytokines and increased
angiogenesis [8, 17]. Therefore, evaluation of the effects of
sorafenib on keloid disease seems timely and pertinent.
Previously, we reported the potential role of sorafenib in the
inhibition of epithelial-mesenchymal transition in hepatocytes
[18]. Here, we demonstrated that sorafenib not only reduced
the proliferation, invasion, and ECM production of KFs in
vitro but also inhibited KF migration, angiogenesis, and col-
lagen accumulation in cultured keloid explants ex vivo, sug-
gesting an attractive therapeutic potential of this drug for
treating skin scars and keloids.
Material and methods
Patients, tissue samples, and chemical reagents
Thirty-six keloid scar specimens in the active stage were har-
vested from 30 patients (13 men and 17 women, age range
20–55 years; details listed in Supplementary Table S1), who
did not receive any treatment for their keloids before surgical
excision. All the samples were exclusively derived from chest
keloids. To minimize individual variation, human fibroblasts
derived from three keloid specimens from different patients
were mixed as a cell pool. Protocols for the handling of human
tissues and cells were approved by the Ethics Committee of
Shanghai Jiao Tong University School of Medicine, and all
tissue samples were donated by the patients for research pur-
poses with written informed consent.
Sorafenib (Bayer Pharmaceuticals) was dissolved in 100 %
DMSO to a stock concentration of 10 mM and stored under
light-protected conditions at −20 °C. On the day of use, soraf-
enib was diluted directly to the desired dose with an identical
final concentration of DMSO. The final concentration of
DMSO did not exceed 0.2 % (v/v) in any experiment de-
scribed below, which was nontoxic to KFs (Supplementary
Fig. S1).
Isolation and culture of normal and keloid
fibroblasts
The chest keloid tissues were excised under local anesthesia
and collected in a 50-ml centrifuge tube, followed by washing
three times in 2.5 % chloramphenicol solution for 5 min each
time. The tissues were soaked three times in phosphate-
buffered saline (PBS) for 5 min each time. Afterward, the
epidermis was removed using a scalpel, and the remaining
dermis was minced into small pieces followed by enzyme
digestion with 0.3 % collagenase II dissolved in Dulbecco’s
modified Eagle’s medium (DMEM) for 4 h at 37 °C on a
rotator. After digestion, the collected cells were centrifuged
at 1500 rpm for 5 min and then resuspended in DMEM
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supplemented with 10 % fetal bovine serum (FBS) and peni-
cillin/streptomycin. The cells were seeded onto a 10-cm cul-
ture dish at a density of 2 × 104/cm2 and cultured in a humid-
ified 5 % CO2 atmosphere at 37 °C. When the cells reached
80 % confluence, they were detached with 0.25 % trypsin-
EDTA and subcultured at the same density. The primary and
first passage cells were used in the following experiments.
Human foreskin fibroblasts were isolated from nine normal
individuals (age range 1–10 years) using the procedure as
described previously [19].
CCK-8 cell proliferation assay
The primary KFs were seeded in 96-well plates with 1000
cells per well along with 200 μl of medium. After being
starved in serum-free medium for 24 h to allow for cell syn-
chronization, the KFs were replaced with fresh culture medi-
um in the presence or absence of sorafenib (5 μM) and then
tested with a cell counting kit-8 (CCK-8; Dojindo, Japan) at
days 2, 4, 6, and 8. Briefly, at each testing time point, 10 μl of
sterile CCK-8 solution was added to each well and incubated
for 2 h at 37 °C, and then the medium was harvested for
measuring the optical density values at 450 nm using a micro-
plate reader (Thermo Scientific). All the assays were per-
formed in quintuplicate and repeated using three cell samples.
Cell cycle analysis
To perform the test, KFs were cultured without or with soraf-
enib at a concentration of 5 μM for 2 and 6 days, respectively.
The cells were then trypsinized, centrifuged at 3000 rpm for
10 min, and stained in ice-cold PBS solution containing
100 μg/ml propidium iodide (PI), 0.1 % Triton X-100,
0.1% sodium citrate, and RNase (1mg/ml). The samples were
incubated at 4 °C overnight, and flow cytometric analyses
were performed using a flow cytometer (Beckman Coulter)
equipped with ModiFit LT v2.0 software. The analyses were
performed on days 2 and 6 and repeated in four cell samples.
EdU incorporation assay
After being treated with or without 5-μM sorafenib for 48 h,
the KFs were exposed to 5-ethynyl-20-deoxyuridine (EdU at a
working concentration of 10 μM) in culture medium for
additional 3 h. EdU incorporation was detected at room tem-
perature using the Click-iT™ EdU Alexa Fluor Imaging kit
(Invitrogen/Molecular Probes) according to the user’s manual.
The cells were fixed in 3.7 % formaldehyde for 15 min at
room temperature, permeabilized by incubation with 0.5 %
Triton X-100 in PBS for 20 min, and then stained with the
Click-iT™ reaction cocktail for 30 min, followed by staining
with Hoechst 33342 dye for 30 min. The EdU-positive cells
(red) and Hoechst-positive cells (blue) were imaged under a
fluorescent microscope (Olympus, Japan) and counted using
Image-Pro Plus (IPP) 6.0 software (Media Cybernetics). The
incorporation ratio of EdU-positive cells was shown as the
percentage of EdU-positive cells of total Hoechst-positive
cells. The results were counted in five randomly selected
fields and repeated in three independent experiments.
RNA isolation and real-time quantitative PCR
Total RNA isolation and reverse transcription were performed
essentially as previously described [20]. Quantitative PCR
(qPCR) was performed using a Power SYBR Green PCR
master mix (Applied Biosystems) in a real-time thermal cycler
(Stratagene). The amplified complementary DNA (cDNA)
products were normalized with the hypoxanthine
phosphoribosyltransferase 1 (HPRT1) cDNA content. The
primers for real-time qPCR analysis are listed in
Supplementary Table S2. Each assay was performed in tripli-
cate and repeated in three cell samples.
Cell migration assay
A transwell system and an in vitro scratch wound assay were
used to evaluate cell migration. For the in vitro wound assay,
when reaching 90% confluence in 6-well plates, the KFs were
treated with 10 μg/ml mitomycin C (Sigma) for 2 h and
washed with basal media. The cell monolayer was scratched
with a sterile 200-μl pipette tip and incubated in the culture
medium with or without sorafenib (5 μM) for 24 h.
Photographs were taken after scratching and at the indicated
time point. The photographed area was quantified with
computer-assisted image analysis using IPP 6.0 software.
The results are presented as a percentage of the area of the
scratch filled by the KFs. The data were acquired from five
randomly selected high-power fields.
A transwell system (Merck Millipore, 8-μm pore size) was
used for the assay. Briefly, KFs were starved for 12 h in serum-
free DMEM. Then, the cells were harvested and seeded in the
upper compartment of the chamber in 24-well plates using a
total of 1 × 104 cells in 0.1 ml of serum-free DMEM with or
without sorafenib (5 μM), and the bottom well was filled with
0.6 ml of DMEMplus 10% FBS. The cells were incubated for
24 h. Afterward, a cotton swab was used to remove the
nonmigrated cells on the upper surface of the membrane,
and the migrated cells on the bottom surface of the filter mem-
brane were fixed in 4 % paraformaldehyde and stained with
DAPI. The numbers of the migrated cells were obtained by
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counting the stained cells in five randomly selected fields
under the microscope.
Cell invasion assay
A cell invasion assay was conducted as described previously
[21]. Briefly, KFs in a total of 5 × 104 cells were seeded into
the upper compartment of the chamber coated with Matrigel
(BD Biosciences) along with DMEM containing 2 % FBS
with or without sorafenib (5 μM) in a total volume of
0.1 ml, and the lower chamber was filled with DMEM plus
10 % FBS in a total volume of 0.6 ml. After 24 h of culture,
the nonmigrated cells on the upper surface of the membrane
were removed with a cotton swab, and the migrated cells that
crossed theMatrigel barrier on the bottom surface of the mem-
brane were fixed, stained with DAPI, and counted in five
random fields. The mean value for each chamber was deter-
mined from three independent experiments.
Luciferase assay
KFs in a 24-well plate were co-transfected with (CAGA)12-
Lux reporter (200 ng per well) and pRL-SV40 plasmid (5 ng
per well). After transfection for 24 h, the cells were incubated
in serum-free medium in the absence or presence of sorafenib
for an additional 12 h prior to harvesting. Luciferase activity
was detected using a Dual Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions.
ELISA assay
After 18 h of incubation with or without sorafenib (5 μM) in
serum-free culture medium, the released TGF-β1 protein from
KFs was measured using an ELISA Development Kit
(Anogen) according to the manufacturer’s instructions with
an absorbance measurement at a wavelength of 450 nm.
Similarly, the concentration of VEGF in the supernatant was
determined by a human VEGF ELISA kit (ExCell Bio). All
the assays were performed in triplicate and repeated in three
cell samples.
Western blotting analysis
After 4 h of incubation in the absence or presence of sorafenib
as indicated, total protein was extracted with RIPA lysis buffer
as described previously [22]. The prepared protein was sub-
jected to SDS-PAGE and subsequently transferred onto PVDF
membranes. The membranes were incubated with primary
antibodies as indicated in the figures, followed by incubation
with appropriate HRP-conjugated secondary antibodies
(Jackson ImmunoResearch). The protein bands were eventu-
ally visualized using an enhanced chemiluminescence (ECL)
detection kit (Amersham). The primary antibodies against
Phospho-Erk1/2 (Thr202/Tyr204), Erk1/2, Phospho-p38
MAPK (Thr180/Tyr182), p38 MAPK, Phospho-SAPK/JNK
(Thr183/Tyr185), SAPK/JNK, Phospho-Smad2 (Ser465/467),
and Smad4 were purchased from Cell Signaling Technology.
The rest include antibodies against β-actin (Sigma-Aldrich),
Smad2/3 (BD Biosciences), Phospho-Smad3 (Ser423/425;
Invitrogen), and Smad7 (Santa Cruz).
Ex vivo explant culture of human keloid tissue
After the harvest of excised keloid tissue under aseptic condi-
tions, the epidermis was removed, and the left dermis was cut
into 3 mm× 2 mm× 2 mm small pieces using a scalpel. The
keloid dermal fragments were divided into three groups and
seeded onto 10-cm culture dishes for 3 days in 6 ml of DMEM
containing 10 % FBS as described previously [23, 24]. After
tissue attachment, the medium was replaced with different
doses of sorafenib (0, 5, and 20 μM). Representative micro-
graphs were obtained in the same location where the KFs were
scratched from at the different time points on days 2, 4, and 7.
After treatment with sorafenib for 7 days, the migrated KFs
were collected and counted using a hematocytometer.
Histological and immunohistochemical analyses
The keloid specimens were fixed in 4 % paraformaldehyde at
4 °C overnight, embedded in paraffin blocks, and sectioned to
5-μm thicknesses. The sections were stained with hematoxylin
and eosin (H&E) for routine examination. In addition, the
keloid sections were incubated with antibodies against
Phospho-Smad2/Smad3, Phospho-Erk1/2, CD31, CD34, col-
lagen I, and collagen III at a dilution of 1:500. The bound
antibodies were eventually visualized using 3,3′-diaminoben-
zidine (DAB) as a chromogen (Dako), and the slides were
counterstained with hematoxylin. The numbers of CD31+
and CD34+ vessels were obtained in six randomly selected
fields under the microscope.
Statistical analysis
All data are presented as the mean ± standard deviation (SD),
and the statistical analyses were analyzed using the statistical
software Statistical Package for the Social Sciences (SPSS
version 19.0). A Student’s t test was applied to analyze the
difference between the control and sorafenib-treated groups.
p < 0.05 was considered statistically significant.
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Results
Elevated levels of phosphorylated forms of Smad2/Smad3
and Erk-1/2 in keloids
Keloid disease is a fibroproliferative lesion that forms in the
dermis during a prolonged wound healing period [25]. The
most striking feature that distinguishes normal skin from hu-
man keloid samples is the presence of an undulating dermal-
epidermal junction and skin appendages in the dermis (i.e.,
hair follicles, sweat glands, and sebaceous glands), with the
keloid epidermis being thickened with flattened rete ridges
and dermal papillae (Fig. 1a, b). Histopathological analysis
also revealed that numerous thick bundles of collagenous ma-
trices were arranged in a reticular manner to form a character-
istic whorled pattern (Fig. 1b).
Numerous studies have recognized that TGF-β signaling
plays a vital role in fibropathogenesis [26, 27]. Hence, we
first detected whether TGF-β signaling was upregulated in
human keloid samples. Indeed, immunohistochemical analy-
sis in the keloid sections showed intense phosphorylated
forms of Smad2/Smad3 (Fig. 1c), which are central mediators
of intracellular TGF-β signal transduction [28]. Meanwhile,
the phosphorylation of p44/42 MAPK (Erk1/2) was enhanced
in human keloids but not normal skin (Fig. 1d). These obser-
vations suggested that both TGF-β/Smad and MAPK/ERK
signaling pathways were highly activated in human keloids,
making them potential pharmacological targets for the clini-
cal treatments of keloids.
Sorafenib blocked intracellular signaling cascades
in KFs
The findings above prompted us to seek small chemicals
that target both TGF-β/Smad and MAPK/ERK signaling
pathways. As the first FDA-approved multikinase inhibitor
in cancer therapy, sorafenib is known to target a couple of
receptor tyrosine kinases [16]. To evaluate the efficacy of
sorafenib on the intracellular signal transduction that is in-
volved in keloid pathogenesis, we isolated primary fibro-
blasts from human keloid samples, which have been widely
used as an in vitro model to study wound healing and drug
metabolism [29, 30]. As shown in Fig. 2a, sorafenib evident-
ly abrogated the phosphorylation of Smad2 and Smad3 at a
workable concentration of 5 μM, whereas the expression of
Smad4 and Smad7 was unaffected. Simultaneously, sorafe-
nib reduced the phosphorylated forms of p44/42 MAPK
(Erk1/2) as well as SAPK/JNK, but not p38 MAPK
(Fig. 2a). Given the vital role of TGF-β signaling in KF
activation after wounding [9, 13], we then detected the im-
pact of sorafenib on this signaling using (CAGA)12-Lux, a
luciferase reporter that contains 12 copies of the Smad-
binding element [31]. Notably, this reporter was capable of
being inhibited by sorafenib in a dose-dependent manner
(Fig. 2b). Moreover, sorafenib resulted in an evident de-
crease of TGF-β1 and VEGF transcripts and extracellular
secretion, indicating that both the mRNA and protein levels
of TGF-β1 and VEGF were inhibited after sorafenib treat-
ment (Fig. 2c, d). Taken together, these data revealed that
Fig. 1 The aberrant activation of
TGF-β/Smad and MAPK/ERK
signaling pathways in keloids. a
Schematic representation of a
keloid and its extra-lesional tissue
samples (the sample harvested
from the same patient as an
internal control). b Histological
analysis of normal skin, keloid,
and its extra-lesional tissue
samples using H&E staining. c, d
Immunohistochemical staining
using antibodies against Phospho-
Smad2/3 and Phospho-Erk1/2
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sorafenib acts as an effective inhibitor of TGF-β/Smad and
MAPK/ERK signaling cascades in vitro.
Sorafenib inhibited cell proliferation and the cell
cycle in KFs
Due to the aberrant proliferation of dermal fibroblasts that
have been shown to contribute greatly to keloid overgrowth
and expansion [8, 32], we then investigated the ability of
sorafenib to modulate the proliferation of KFs. As determined
by CCK-8, a colorimetric assay used to measure cell viability
and cytotoxicity, sorafenib significantly inhibited the prolifer-
ation of KFs in a time-dependent manner compared with the
nontreated group (Fig. 3a). Additionally, the exposure of KFs
to sorafenib for 2 and 6 days eventually led to a decrease of
cells in the G2/M phase and an increase of cells in G0/G1 at
day 6 (Fig. 3b). No significant difference was found in the
sub-G1 population between the control and sorafenib-treated
groups at both days 2 and 6 (p > 0.05; data not shown).
Next, we delineated the inhibitory effects of sorafenib on
cell growth using an EdU incorporation assay. As shown in
Fig. 3c, the DNA synthesis in KFs was rapidly decreased by
sorafenib as fewer KFs were found to be able to incorporate
EdU compared with the cell number of nontreated group.
Quantitative analysis revealed a noticeable difference in the
percentage of EdU-positive cells between the control and
sorafenib-treated groups (p < 0.001, Fig. 3d), indicating that
sorafenib is likely to inhibit cell proliferation via cell cycle
arrest.
Sorafenib attenuated collagen production and ECM
accumulation in KFs
Afterward, we explored whether sorafenib treatment could
reduce the endogenous expression of collagen and other
ECM molecules in primary KFs. Impressively, the exposure
of KFs to sorafenib for 48 h remarkably inhibited both tran-
scriptional and translational levels of fibrotic matrix
Fig. 2 Sorafenib antagonizes intracellular signaling in vitro. a KFs were
treated with increasing doses of sorafenib (0, 2.5, 5, and 10 μM) for 4 h
and harvested for western blot (WB) analysis to assess the intracellular
signaling as indicated. b As described in the BMaterial and Methods^
section, KFs seeded in 24-well plates were transfected with (CAGA)12-
Lux reporter, incubated with increasing doses of sorafenib (0, 2.5, 5, and
10 μM) for 8 h and then analyzed with a luciferase assay. c After
treatment with sorafenib (5 μM) for 24 h, the KFs were subjected to
real-time qPCR to detect the gene expression levels of two major
profibrotic members of the TGF-β superfamily (TGF-β1 and TGF-β2)
and VEGF. d The concentrations of secreted TGF-β1 and VEGF in the
supernatant were determined by ELISA after 18 h of sorafenib treatment
(5 μM). Each assay was performed in triplicate and repeated in four
independent cell pools (n = 4, 12 samples). The asterisks denote
significant differences (p < 0.05) within experiments, as determined by
the Student’s t test
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components, such as types I and III collagens (COL1 and
COL3) (Fig. 4a, b), implying a protective role for sorafenib
in counteracting collagen production and accumulation.
Likewise, sorafenib attenuated the transcriptional level of fi-
bronectin (Fig. 4b), a glycoprotein that functions as a scaffold
for the ECM network facilitating cell proliferation and migra-
tion [33]. These results were further supported by assessing
the expression profiles of matrix metalloproteinases (MMPs)
and the tissue inhibitors of MMPs (TIMPs), which are essen-
tial secreted proteins known to maintain ECM turnover and
homeostasis [34]. As shown in Fig. 4c, sorafenib raised the
ratio of MMP-2/TIMP-1 and MMP-13/TIMP-1, which indi-
cates a net destruction of ECM by sorafenib in KFs
(p < 0.05). Furthermore, sorafenib elicited a decreased expres-
sion of pro-fibrotic genes, such as connective tissue growth
factor (CTGF), interleukin-6 (IL-6), and interleukin-8 (IL-8)
(Fig. 4d). Similarly, the expression levels of antifibrotic genes
TGF-β3 and IFN-γ were enhanced by approximately 50 and
80%, respectively, after treatment with sorafenib (Fig. 4e). On
the other hand, sorafenib downregulated the expression levels
of IL-6 and IL-8 but exhibited negligible effects on TNF-α and
IFN-γ transcripts in normal fibroblasts (NFs) derived from
human foreskins (Supplementary Fig. S2). Collectively, these
results demonstrated that sorafenib exerts an antifibrotic role
in KFs.
Sorafenib eliminated cell migration and the invasion
of KFs
Because the enhanced migration and invasion properties of
dermal fibroblasts are the critical parameters in the develop-
ment of keloid disease [8, 32], we wondered if sorafenib
would affect the cell behavior of KFs in vitro. As shown in
Fig. 5a, KFs in the control group efficiently migrated into the
scratched area to such an extent that the wound boundary was
not apparent after 24 h of culture. In contrast, the migration
capacity of KFs was evidently abrogated, as only 22.65
± 3.33 % of the scratched area was filled after treatment with
sorafenib (p < 0.001; Fig. 5b). These data were further validat-
ed by a transwell assay. As observed in Fig. 5c, sorafenib
could strikingly reduce the number of cells that migrated
across the filter membrane to the bottom surface. Compared
with the nontreatment group (average 167 ± 7, n = 3),
Fig. 3 Treatment with sorafenib inhibits KF proliferation. a The cell
viabilities of KFs treated with or without sorafenib (5 μM) were
measured with a CCK-8 assay at days 2, 4, 6, and 8. b The effect of
sorafenib (5 μM) on the cell cycle profiles was further evaluated by
flow cytometry analysis. c After treatment with sorafenib (5 μM) for
96 h, KFs were incubated with EdU (10 μM) for an additional 3 h. The
samples were imaged under a fluorescent microscope. d The ratio of
EdU-positive cells to Hoechst-labeled cells in each group was
determined. All the experiments were repeated in three independent cell
pools (n = 3, 9 samples).G0/G1 gap between end of M-phase and start of
S-phase, S DNA duplication phase, G2 gap between end of S-phase and
start of M-phase, M mitosis
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sorafenib led to a noticeable reduction in the number of mi-
grated cells to approximately 43 % (average 72 ± 7, n = 3)
(p < 0.001; Fig. 5d).
Meanwhile, the impact of sorafenib on cell invasion was
assessed by Transwell invasion assay. As shown in Fig. 5e,
control KFs had successfully invaded through the Matrigel
and across the filter membrane after 24 h of incubation, where-
as sorafenib-treated cells showed a greatly decreased invasive
capability. Quantitative analysis by manual cell counting re-
vealed that the number of invaded cells in the sorafenib-
treated group was 87 % less than that in the control group
(p < 0.05, Fig. 5f). Additionally, treatment with sorafenib
largely blunted the transcriptional activities of MMP1 and
MMP3 (p < 0.05, Fig. 5g), which are required to mediate cell
invasion during wound repair and even tumor metastasis [35,
36]. Therefore, sorafenib appears to counteract the elevated
capacities of migration and invasion in KFs.
Sorafenib suppressed KF migration
and proliferation in cultured keloid explants
The in vitro results outlined above encouraged us to further
evaluate the therapeutic potential of sorafenib in keloid dis-
ease. In the absence of suitable animal models, we here ap-
plied an ex vivo keloid explant culture that represents a feasi-
ble clinically relevant model for studying keloid pathobiology
as well as preclinical testing of potential therapeutics [23, 24].
In the vehicle group, spindle-like KFs initially migrated out
from the edges of the explanted tissue and extended well into
the Petri dish over a week. In contrast, treatment with sorafe-
nib for 7 days induced a progressive decline in the number of
KFs to approximately 74–95 % at day 7 (Fig. 6a, b), which
may be due to a combination of its negative roles in cell
migration and proliferation.
Sorafenib depleted CD31+/CD34+ vessels
and reduced collagen accumulation in keloid explant
culture
Histologically, keloids contain an increased blood vessel den-
sity compared with normal dermis or normal scars [37].
Hence, we wondered whether sorafenib would repress angio-
genic activity. To better mimic the in vivo response to sorafe-
nib, human keloid explants were embedded and sectioned for
further analyses. As expected, we observed reduced cellularity
and microvasculature in sorafenib-treated tissue sections
(Fig. 7a). Interestingly, treatment with sorafenib at the higher
concentration of 20μM for 7 days caused a drastic decrease in
the CD31-positive density, a traditional marker for endothelial
cells (Fig. 7b). Quantification data revealed that approximate-
ly 65 % of CD31+ cells were reduced by sorafenib (Fig. 7c).
Meanwhile, the microvascular endothelial cells were notice-
ably declined to 75 % in the papillary and reticular dermis, as
visualized by CD34 immunostaining (Fig. 7d, e).
Fig. 4 The antifibrotic role of sorafenib in counteracting ECM
production and accumulation. After treatment with sorafenib (5 μM) for
48 h, KFs were subjected to Western blotting to determine the effects of
sorafenib on the collagen accumulation (a). Similarly, real-time qPCR
was performed to detect the roles of sorafenib on the gene expression
levels of ECMmolecules (b), the ratio ofMMPs/TIMP-1 (c), pro-fibrotic
genes (d), and antifibrotic genes (e). Each assay was performed in
triplicate and repeated in three independent cell pools (n = 3, 9 samples)
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Finally, we elucidated the potential anti-fibrotic effects of
sorafenib in cultured keloid explants in situ. Compared with
the vehicle group, treatment with sorafenib for 7 days reduced
the immunoreactivity of collagen I (Fig. 8a), which is in ac-
cordance with theWestern blotting and real-time qPCR results
in KFs (Fig. 4a, b). Similarly, the accumulation of collagen III
in human keloid explants was noticeably diminished by soraf-
enib even at a lower concentration (Fig. 8b). Collectively,
these data suggested that sorafenib exerts its anti-angiogenic
and anti-fibrotic properties in an ex vivo keloid model.
Discussion
Keloid disease is an extremely complex disorder principally of
the human dermis with notorious recurrence after various
therapies used alone or in combination, leading to the concept
that a keloid is a benign skin tumor [8, 17]. However, differing
entirely from other tumors, keloids have only been observed
in humans and have never been successfully reproduced in
any animal models [25], probably reflecting our limited un-
derstanding of their etiology. Because human KFs are main
inductive cells that initially show a marked infiltration in le-
sion tissue and subsequently mediate elevated ECM deposi-
tion [1, 9], innovative strategies that focus on targeting KFs by
novel compounds may have important theoretical and practi-
cal implications for the clinical management of keloids. In the
present study, we identified a novel property of sorafenib to
antagonize intracellular signaling, and consequently, to sub-
stantially inhibit cell proliferation, migration, invasion, and
ECM deposition using an in vitro cellular model (Figs. 2, 3,
4, and 5). Moreover, its anti-keloid efficacy was demonstrated
in human cultured keloid explants, whereby sorafenib
Fig. 5 Sorafenib depresses the
migratory and invasive abilities of
KFs. a, b The KFs were grown to
a confluent monolayer and treated
with mitomycin C (10 μg/ml) for
2 h to inhibit cell proliferation.
The confluent monolayer was
wounded by manually scratching
with a sterile pipette tip and
following further incubation with
or without sorafenib (5 μM) for
24 h. The scratched areas filled by
migrated KFs were observed at
24 h post-scratching and
quantified using IPP software. c,
d As determined by transwell
assay, the migratory KFs were
visualized by imaging the nuclei
labeled with DAPI. The number
of migrated cells was counted in
five randomly selected fields. e, f
KFs were seeded in the upper
chamber coated withMatrigel and
incubated in the absence or
presence of sorafenib (5 μM) for
24 h. The invasive KFs were
visualized by imaging the DAPI-
labeled nuclei and counted in five
random fields. g The effects of
sorafenib on the transcriptional
levels ofMMP-1 andMMP-3. All
the experiments were repeated in
three independent cell pools
(n = 3, 9 samples)
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impeded KF migration and proliferation as well as angiogen-
esis and collagen accumulation (Figs. 6, 7, and 8). Encouraged
by these findings, considerable clinical improvement and ther-
apeutic value would be expected to cure keloids or improve
their appearance. Therefore, we firmly believe that this chem-
ical may have a much broader hands-on role than it is current-
ly known.
It is increasingly recognized that MMPs are the major pro-
teinases responsible for ECM degradation and remodeling
[38]. An imbalance in the expression of MMPs and their in-
hibitors (TIMPs) is associated with the pathological process of
dermal fibrosis in keloids [34, 35]. Specifically, MMP-2 and
MMP-13 contribute extensively to break down types I and III
collagens, the most abundant types of collagen in keloids and
hypertrophic scars [32, 39]. Here, we observed that sorafenib
not only reduced the expression of fibrotic ECM components
(Figs. 4a, b and 8) but alsomodulated theMMPs/TIMP-1 ratio
to potentially promote the degradation of ECM proteins
(Fig. 4c), thereby promising a reverse of the established fibro-
sis in keloids. Additionally, several members of the MMP
family were reported to increase the migratory activity of
KFs and tumor cells by degrading the basement membrane
[1, 40]. For instance, both MMP1 and MMP3 actively partic-
ipate in the ECM degradation of fibrotic scar tissue. However,
it still remains controversial whether the expression of these
two MMP enzymes would be elevated in keloids. The major-
ity of literatures reported the upregulation of MMP1 and
MMP3 [32, 39, 41], because they greatly contributed to the
invasion of KFs, allowing the keloids to extend beyond the
wound boundary. We speculated that the different stages of
keloid development may attribute to the differential expres-
sions of MMPs. The keloid specimens we harvested in this
study were in a very active stage with aggressive invasion in
our clinical observation, which may lead to an enhanced ex-
pression of them. Thus, MMP-1 and MMP-3 transcripts were
apparently decreased after treatment with sorafenib (Fig. 5g),
providing a possible explanation for its potent roles on con-
trolling KF migration as well as tumor cell invasion and
metastasis.
To fully elucidate the underlying mechanism of keloid
pathogenesis and recurrence, it is essential to appreciate how
normal skin repair is regulated and how this process goes
awry. Normal wound healing is tightly controlled by a com-
plicated network of distinct profibrotic and antifibrotic
Fig. 6 Sorafenib inhibits the migration and proliferation of cultured
keloid explant-derived cells. a Three-millimeter keloid tissue explants
were maintained in medium for 3 days and then treated with increasing
concentrations of sorafenib (0, 5, and 20 μM) for additional days as
indicated. Representative micrographs are shown in the same location
where KFs were scratched at different time points as indicated. b The
migrated KFs were collected at day 7 and counted using a
hematocytometer. The experiment was repeated using four independent
keloid tissue samples from different patients (n = 4)
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cytokines [1, 9]. With increased knowledge of this disease,
TGF-β/Smad signaling has long been considered a pivotal
fibrogenic inducer and therefore an important pharmacologi-
cal target for treating keloids. In the past decade, several
antifibrotic strategies have been successfully established
based on the blockade or elimination of latent TGF-β signal-
ing at various transduction steps. For example, neutralizing
antibodies against TGF-β have been shown to prevent in-
creased ECM deposition and reduce the rate of collagen syn-
thesis in keloids and hypertrophic scars [13, 42, 43]. Similarly,
Fig. 7 Sorafenib depletes angiogenesis in keloid explant culture. a After
being cultured with or without sorafenib for 7 days, the keloid explants
from different individuals (n = 3) were sectioned and stained with H&E
for histological analysis. b, e The sections as indicated in the figures were
also subjected to immunohistochemical analysis using antibodies against
CD31 and CD34. Brown coloration indicates positive staining of related
markers. The numbers of the CD31-positive endothelial cells and CD34-
positive microvascular endothelial cells were counted in six randomly
selected fields for each sample under a microscope
Fig. 8 Sorafenib reduces
collagen accumulation in keloid
explant culture. a, b As described
in Fig. 7, the keloid explants from
different individuals (n = 3) were
sectioned and subjected to
immunohistochemical analysis.
The immunoreactivity of collagen
I (COL1) and collagen III (COL3)
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the injection of TGF-β antibodies into the margins of healing
dermal wounds in adult rats was shown to neutralize TGF-β
signaling and thereby repair wound healing to reduce scar-
tissue formation [44]. In addition to these protein-based ther-
apies, small molecules and biological agents aimed at
blocking this signaling cascade will provide an appropriate
strategy for curing keloids. However, until now, widely effec-
tive therapeutic interventions for keloids have been currently
lacking. The present study clearly showed that sorafenib
counteracted TGF-β signaling by repressing the levels of both
TGF-β1 expression and intracellular Smad2/3 phosphoryla-
tion (Fig. 2), suggesting that the sorafenib-mediated inhibition
of cell proliferation, migration, and fibrotic matrix deposition
is at least partly due to its interference with TGF-β/Smad
signaling. In addition to TGF-β signaling, a growing body
of growth factors has been reported to be dysregulated in
keloid pathogenesis and recurrence [1, 9]. Here, we observed
the inhibitory effects of sorafenib on the expression of
profibrotic genes VEGF, CTGF/CCN2, IL-6, and IL-8
(Figs. 2c and 4d), together with simultaneously synergistic
effects on the expression of the antifibrotic genes TGF-β3
and IFN-γ (Fig. 4e). Indeed, further definition of the exact
nature of the crosstalk among cellular signaling pathways
may provide a progressively clearer understanding of the mo-
lecular mechanisms underlying keloid pathogenesis and lead
to new approaches for future therapeutic improvements.
Over the past decades, tremendous basic research efforts
have been made to investigate the roles of receptor tyrosine
kinases that are currently known to be key regulators of
proliferative, inflammatory, and fibrotic diseases of the der-
mis [45]. Tyrosine-kinase inhibitors (TKIs), which target
ligand-mediated receptors and intracellular signaling path-
way activation, have a better opportunity for efficacy in the
clinical treatments of these disorders, including keloids. As
one of the most well-known TKIs, sorafenib blocks both
Raf and a series of tyrosine kinases, such as PDGFR and
VEGFR [16], suggesting a number of advantages over tra-
ditional approaches. Most importantly, the safety and toler-
ability of sorafenib have been well documented as it has
been an FDA-approved agent for nearly a decade [14].
Additionally, the administration of sorafenib through topical
injection or sustained systemic drug delivery to target spe-
cific diathesis may have significant clinical benefits. It is
anticipated that systemic side effects known for sorafenib
will not occur, if local administration is given at a low
dose. As a matter of fact, an independent clinical trial is
ongoing to assess the efficacy of sorafenib in patients with
extensive keloids (see at https://clinicaltrials.gov/). In
addition to sorafenib, the anti-keloid effectiveness of sever-
al potent TKIs has already been observed [46–48]. Despite
improved insights into this therapeutic avenue, uncertainty
and limitations remain in the translational research from the
literature into its clinical practice. Certainly, more detailed
investigations will be performed to warrant the potential
application of sorafenib in the future.
In summary, we showed that the blockade of TGF-β/Smad
and MAPK/ERK signaling pathways by sorafenib can effec-
tively inhibit the proliferation, migration, cellular invasion,
and ECM accumulation of KFs and concomitantly reduce
the expression of inflammatory cytokines and inhibit angio-
genesis, suggesting sorafenib as an attractive therapeutic in-
tervention in the clinical setting of keloid disorder.
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